Atea Pharmaceuticals, Inc. (AVIR) Q3 2026 Earnings Call Transcript
Atea Pharmaceuticals, Inc. AVIR
$4.30
▼ -2.49%
($-0.11)
⬇️ Below Yest. Low
Open
$4.37
Prev Close
$4.41
Day Range
$4.24 – $4.45
52W Range
$2.87 – $6.45
Market Cap
$353.70M
Beta
0.70
EPS (TTM)
$-2.09
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-30 |
| Shares Out. | 80,200,000 |
| Website | ateapharma.com ↗ |
| Phone | 13026587581 |
| Employees | 55 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$32.9M |
| Free Cash Flow | -$152.1M |
| Total Assets | $232.3M |
| Total Liabilities | $28.1M |
| Equity | $204.2M |
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Atea Pharmaceuticals, Inc. is a publicly traded company under the ticker symbol AVIR on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-11-01)
📰 Latest News for AVIR
Atea Pharma (AVIR) Q3 2026 Earnings Call Transcript
Atea Pharmaceuticals (NASDAQ:AVIR) Posts Narrower Q3 Loss as C-FORWARD Readout Looms
What Atea Pharmaceuticals (AVIR) Said on Its Q3 Earnings Call
Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
CORRECTION: Atea Pharmaceuticals Q3 EPS $(0.40) Beats $(0.42) Estimate
Atea Pharmaceuticals Q3 2026 Earnings Call Transcript
Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital